Issue 89, 2014

Lumazine synthase protein cage nanoparticles as modular delivery platforms for targeted drug delivery

Abstract

Lumazine synthase protein cage nanoparticle isolated from Aquifex aeolicus (AaLS) is developed as a modular delivery nanoplatform that genetically acquires either tumor vasculature targeting peptides or hepatocellular carcinoma cell surface targeting peptides on its surface. The targeting peptide bearing AaLS effectively delivers its cargo to their target cancer cells.

Graphical abstract: Lumazine synthase protein cage nanoparticles as modular delivery platforms for targeted drug delivery

Supplementary files

Article information

Article type
Communication
Submitted
11 Sep 2014
Accepted
24 Sep 2014
First published
25 Sep 2014

RSC Adv., 2014,4, 48596-48600

Author version available

Lumazine synthase protein cage nanoparticles as modular delivery platforms for targeted drug delivery

J. Min, S. Kim, J. Lee and S. Kang, RSC Adv., 2014, 4, 48596 DOI: 10.1039/C4RA10187A

To request permission to reproduce material from this article, please go to the Copyright Clearance Center request page.

If you are an author contributing to an RSC publication, you do not need to request permission provided correct acknowledgement is given.

If you are the author of this article, you do not need to request permission to reproduce figures and diagrams provided correct acknowledgement is given. If you want to reproduce the whole article in a third-party publication (excluding your thesis/dissertation for which permission is not required) please go to the Copyright Clearance Center request page.

Read more about how to correctly acknowledge RSC content.

Social activity

Spotlight

Advertisements